0RA2.L - Poxel S.A.

LSE - LSE Delayed price. Currency in EUR
1.6000
0.0000 (0.00%)
As of 08:29AM BST. Market open.
Stock chart is not supported by your current browser
Previous close1.6000
Open5.6442
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.6000 - 1.6000
52-week range1.6000 - 1.6000
Volume78,599
Avg. volumeN/A
Market cap394,955
Beta (5Y monthly)1.36
PE ratio (TTM)N/A
EPS (TTM)-0.8300
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Poxel Reports Cash and Revenue for the First Quarter 2023 and Provides Corporate Update

    LYON, France, May 17, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the first quarter ended March 31, 2023.

  • Business Wire

    Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023

    LYON, France, May 16, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of the meeting notice for the Annual General Meeting, which will be held on June 21, 2023 at 9 am CEST at the Mercure Hotel, Lyon Centre Saxe Lafayette, 29 rue de Bon

  • Business Wire

    Poxel Announces TWYMEEG® (Imeglimin) Fiscal Year 2022 Sales

    LYON, France, May 15, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced TWYMEEG® (Imeglimin) Fiscal Year (FY) and fourth quarter 2022 results, as recently published by Sumitomo Pharma (Sumitomo), its partner commercializing TWYMEEG in Japan.

  • Business Wire

    Poxel Announces Upcoming Participation at the JMP Securities Life Science Conference

    LYON, France, May 11, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the JMP Securities Life Science Conference, to be held in New York, NY, Monday, May 15, and Tuesday, May 16, 2023.

  • Business Wire

    Poxel Announces Availability of the 2022 Universal Registration Document and Provides Update on Accounts Settlement

    LYON, France, May 03, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced that the Universal Registration Document (Document d’Enregistrement Universel) for the year ended December 31, 2022 has been filed with the French market authority (Autorité des Marchés Financ

  • Business Wire

    Poxel Announces Multiple TWYMEEG® (Imeglimin) Abstracts Accepted for Oral Presentation

    LYON, France, April 20, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today that nine abstracts based on Imeglimin Phase 2b and Phase 3 clinical trials have been accepted for oral presentations at the 66th Annual Meeting of the Japanese Diabe

  • Business Wire

    Poxel Reports Financial Results for Full Year 2022 and Provides Corporate Update

    LYON, France, March 23, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its results for the year ended December 31, 2022 and provided a corporate update.

  • Business Wire

    Poxel Announces Cash Runway Extended Through Q2 2025 Based upon Debt Restructuring Agreement and New Equity-linked Financing Facility

    LYON, France, March 23, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today that is has finalized (1) agreements with its lenders to restructure its existing debt obligations and (2) a new equity-linked financing with IRIS with an initial drawdown of EUR 3

  • Business Wire

    Poxel will Report its 2022 Full Year Results on March 23, 2023

    LYON, France, March 22, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced it will report its 2022 Full year results on March 23, 2023, before market opening.

  • Business Wire

    Poxel to Report its 2022 Full Year Results by the End of March 2023

    LYON, France, March 22, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today that it will report its 2022 full year results by the end of March 2023.

  • Business Wire

    Poxel Announces Upcoming Participation at Evercore ISI’s NASH Renaissance Event

    LYON, France, March 15, 2023--Regulatory News: POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the NASH Renaissance virtual event hosted by Evercore ISI on Thursday, March 30, 2023.

  • Business Wire

    Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology

    LYON, France, March 07, 2023--Regulatory News: POXEL SA (Euronext : POXEL – FR0012432516), clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced publication in Journal of Hepatology of positive results for DESTINY-1 (Deuterium-stabilized R-pioglitazone [PXL065] Efficacy and Safety Trial In NASH), a 36-week dose-ranging Phase

  • Business Wire

    Poxel Announces Publication in Kidney International of PXL770 Preclinical Results in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    LYON, France, March 01, 2023--Regulatory News: POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today the publication of preclinical results in autosomal dominant polycystic kidney disease (ADPKD) for PXL770, a novel, first-in-class direct adenosine monophosphate-acti

  • Business Wire

    Poxel Reports Cash and Revenue for the Full Year 2022 and Provides Corporate Update

    LYON, France, February 15, 2023--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its cash position and revenue and provided a corporate update for the twelve months ended December 31, 2022.

  • Business Wire

    Poxel Receives Orphan Drug Designation from the European Commission for PXL770 and PXL065 for Treatment of Adrenoleukodystrophy

    LYON, France, January 25, 2023--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that European Commission has granted orphan drug designation (ODD) for PXL770 and PXL065 for the treatment of adrenoleukodystrophy (ALD). The decision follows a positive opinion from the Committ

  • Business Wire

    Poxel Announces Upcoming Participation at Investor Conferences

    LYON, France, January 04, 2023--POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its upcoming participation at conferences organized by Oddo BHF and Degroof Petercam to be held in January 2023.

  • Business Wire

    Poxel Announces its Financial Calendar for 2023

    LYON, France, January 03, 2023--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2023.

  • Business Wire

    Poxel Announces Drawdown of the Remaining Two Tranches of its Equity-linked Financing Facility and Provides Corporate Update

    LYON, France, December 22, 2022--POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced the drawdown of the remaining two tranches of the convertible bonds as part of the equity-linked financing facility with Iris Capital Investment (IRIS) representing a total of EUR 2 million.

  • Business Wire

    Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022

    LYON, France, November 08, 2022--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2022.

  • Business Wire

    Poxel Presents DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022

    LYON, France, November 07, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that the results from its Phase 2 study of PXL065 in NASH (DESTINY-1) were presented during the late-breaking session at The Liver Meeting® 2022, hosted by the American Association for the Study

  • Business Wire

    Poxel Announces Upcoming Participation at the Jefferies London Healthcare Conference

    LYON, France, November 07, 2022--POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its participation at the Jefferies London Healthcare Conference, to be held in London from Tuesday, November 15 to Thursday, November 17, 2022.

  • Business Wire

    Poxel Announces Upcoming Presentation at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference

    LYON, France, October 13, 2022--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it is presenting at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference on Monday, October 17th, 2022 at 10:00 am ET (4:00 pm CEST). Thomas Kuhn, CEO of Poxel, and other members

  • Business Wire

    Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022

    LYON, France, October 12, 2022--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that its late-breaking abstract describing the results from its Phase 2 study of PXL065 in NASH (DESTINY-1) has been selected for an oral presentation at The Liver Meeting® 2022, hosted by the A

  • Business Wire

    Availability of Poxel's 2022 Half-Year Financial Report

    LYON, France, October 04, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases, today announces the publication of its half-year financial report as of June 30, 2022.

  • Business Wire

    Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA for Autosomal-Dominant Polycystic Kidney Disease (ADPKD)

    LYON, France, October 03, 2022--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to PXL770 for the treatment of patients with autosomal-dominant polycystic kidney disease (ADPKD). PXL7